Australia markets closed

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.36-1.10 (-11.58%)
At close: 04:00PM EDT
8.37 +0.01 (+0.06%)
After hours: 05:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.46
Open9.43
Bid8.34 x 200
Ask8.40 x 200
Day's range8.31 - 9.55
52-week range4.92 - 24.28
Volume1,583,436
Avg. volume1,032,530
Market cap513.737M
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Replimune Announces $100 Million Private Placement Financing

    - Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA filing expected in 2H 2024 - - Proceeds enable full commercial scale up to support a potential launch in 2H 2025 - WOBURN, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage b

  • GlobeNewswire

    Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com.

  • GlobeNewswire

    Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

    Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today annou